Post on 01-Jan-2017
70 BIBLIOGRAPHY
1 Center for Drug Evaluation and Research [CDER] US Food and
Drug Administration [USFDA] Guidance for Industry Bioavailability
and Bioequivalence-Studies for Orally Administered Drug Prodcuts-
General Considerations Revision 1 Mar 2003 1-23
2 Yuvraj Singh Dangi M L Soni and K P Namdeo Highly Variable
drugs Bioequivalence requirements and Regulatory perspectives
Journal of Current Pharmaceutical Research 3[1] 2010 24-28
3 Central Drugs Standard Control Organization Directorate General of
Health Services Government of India Guidelines for Bioavailability
and Bioequivalence-Studies Mar 2005 1-33
4 Brazilian Sanitary Surveillance Agency Guide For Relative
BioavailabilityBioequivalence Tests Resolution - RE 896 Article-1
May 2003
5 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Food-effect BioavailabilityFed
Bioequivalence studies Dec 2002 1-9
6 Committee for Proprietory Medicinal Products Working Party on
Efficacy of Medicinal Products Note for guidance Investigation of
bioavailability and bioequivalence The European Agency for the
Evaluation of Medicinal Products July 2008 1-29
7 Midha KK Nagai T Bioavailability bioequivalence and
pharmacokinetic studies FIP Bio-international 96 Tokyo Business
center for academic societies Japan 1996
8 World Health Organization Additional guidance for organizations
performing in vivo bioequivalence studies Annex-9 WHO technical
report series 2006 937
9 Saudi Food and Drug Authority Draft bioequivalence requirements
guidelines May 2005 1-41
10 Therapeutic Products Directorate Minister of Health Health Canada
Conduct and analysis of comparative bioavailability studies-Part A
Oral dosage formulations used for systemic effects 1992 1-49
11 Therapeutic Products Directorate Minister of Health Health Canada
Conduct and analysis of comparative bioavailability studies-Part B
Oral Modified Release Formulations 1996 1-129
12 Chow SC Liu JP Design and Analysis of Bioavailability and
Bioequivalence Studies - Revised and Expanded 2nd Edition Marcel
Dekker Inc New York 1992
13 Chow SC and Liu JP Design and analysis of bioavailability and
bioequivalence studies 3rd Edition Chapman HallCRC Press Taylor
amp Francis [New York] 2008
14 Blume H and Midha KK Report of Consensus Meeting Bio-
international rsquo92 Conference on Bioavailability Bioequivalence and
Pharmacokinetic Studies Bad Homburg Germany 20-22 May 1992
Eur J Pharm Sci 1165-171
15 Boddy AW Snikeris FC Kringle RO Wei GCG Oppermann
JA and Midha KK An approach for widening the bioequivalence
acceptance limits in the case of highly variable drugs Pharm Res
1995121865-1868
16 Marzo A Clinical pharmacokinetic registrations file for NDA and
ANDA procedures Pharmacological research Chapter-36 1997 425-
450
17 Therapeutic Products Directorate Minister of Health Health Canada
Discussion paper on Bioequivalence requirements - highly variable
drugs and highly variable drug products issues and options Expert
Advisory Committee on Bioavailability and Bioequivalence [EAC-BB]
Meeting June 26-27 2003
18 Department of Health and Human Services US Food and Drug
Administration Bioavailability and bioequivalence requirements
Drugs for human use Code of federal regulations Title 21 Volume 5
Chapter I Part 32024 Apr 2011
19 Robert P Heaney Factors Influencing the Measurement of
Bioavailability Taking Calcium as a Model J Nutr 131 2001 1344-
1348
20 Westlake WJ Bioavailability and bioequivalence pharmaceutical
formulations In Peace KE [Ed] Biopharmaceu -tical statistics for
drug development Marcell Dekker New York 1988 329-352
21 Investigation of bioavailability and bioequivalence The rules
governing medicinal products in European Community Vol III
addendum-2 1991 149-169
22 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry-waiver of in vivo bioavailability
and bioequivalence studies for immediate-release solid oral dosage
forms based on a biopharmaceutics classification system August
2000 1-13
23 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry-Bioequivalence
recommendations for specific products Jun 2010 1-4
24 Center for Drug Evaluation and Research US Food and Drug
Administration Inspections of clinical facilities and analytical
laboratories conducting bioequivalence studies submitted in ANDAS
Dec 2000 1-5
25 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use General
considerations for clinical trials-E8 ICH triplicate efficacy guidelines
Version-4 Jul 1997 1-13
26 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Structure and
content of clinical study reports-E3 ICH triplicate efficacy guidelines
Version-4 Nov 1995
27 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Guideline for good
clinical practice-E6 [R1] ICH triplicate efficacy guidelines Version-4
June 1996
28 Michael J McGraw Adam N George Shawn P Shearn and Rigel L
Hall editors Principles of Good Clinical Practice Pharmaceutical
Press 1st edition 2010 245-256
29 Central Drugs Standard Control Organization Directorate General of
Health Services Government of India Guide lines on Good clinical
practice 2005
30 World Health Organization Guidelines for GCP for trials on
pharmaceutical products WHO technical report series Annex-3 850
1995 1-35
31 Department of Health and Human Services US Food and Drug
Administration Protection of human subjects Code of federal
regulations Title 21 Volume-1 Chapter- I part 50
32 Department of Health and Human Services US Food and Drug
Administration Institutional review boards Code of federal
regulations Title 21 volume-1 chapter- I part 56
33 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for institutional review boards clinical
investigators and sponsors Exception from Informed Consent
Requirements for Emergency Research July 2006
34 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Investigator responsibilities
protecting the rights safety and welfare of study subjects Oct 2009
35 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Development
safeties update report-E2F ICH Triplicate efficacy guidelines Version
4 Aug 2010
36 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Clinical safety data
management definitions and standards for expedited reporting-E2A
ICH Triplicate efficacy guidelines Version 4 Oct 1994
37 D M Brahankar sunil B Jaiswal Pharmacokinetics Basic
considerations Biopharmaceutics and Pharmacokinetics Vallabh
Prakashan 2008 212-229
38 Center for Drug Evaluation and Research US Food and Drug
Administration ERIn vitroIn vivo correlations Bioavailability and
Bioequivalence Sep 1997
39 D M Brahankar sunil B Jaiswal Invitro-invivo correlation
Bioavailability and Bioequivalence Biopharmaceutics and
Pharmacokinetics A Treatise Vallabh Prakashan 2008 282-305
40 WHO-Research and training in tropical diseases Handbook of good
laboratory practice Quality practices for regulated non-clinical
research and development 2nd edition 2008 9-40
41 Department of Health and Human Services US Food and Drug
Administration Good laboratory practices for nonclinical laboratory
studies Code of federal regulations Title 21 Volume 1 Chapter- I
Part 58
42 Organisation for Economic Co-operation and Development Good
laboratory practice OECD principles and guidance for compliance
monitoring OECD publishing 2005 13-26
43 Jurg PSeiler Good laboratory practice 2nd edition Springer-Verlag
Berlin Heidelberg European Union 2005 59-103
44 Sandy Weinberg Good laboratory practice regulations 3rd edition
revised and expanded Taylor amp Francis e-Library New York 2005
127-148
45 Willa Y Garner Maureen S Barge James P Ussary Good laboratory
practice standards Applications for field and laboratory studies
American Chemical Society 1992 124-132
46 Milton A Anderson GLP essentials a concise guide to good
laboratory practice 2nd edition Interpharm Press 2002 15-30
47 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Exposure-response
relationships-study design data analysis and regulatory applications
Apr 2003
48 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Statistical
principles for clinical trials-E9 ICH harmonised tripartite efficacy
guideline Feb 1998
49 Schuirmann DJ A comparison of the two one-sided test procedure
and the power approach for assessing the equivalence of average
bioavailability J Pharmacokinet Biopharm 15 1987 657-680
50 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Guidance for industry
Statistical approaches establishing bioequivalence Jan 2001 1-45
51 Murray R Spiegel Curve fitting Regression Planes and Correlation
Coefficients Probability and Statistics 2004 278-327
52 Steinijans VW and Hauschke D Update on the statistical analysis of
bioequivalence studies International journal of clinical pharmacology
therapy and toxicology 30[1] 1992 45-50
53 Lloyd R Snyder Joseph J Kirkland Joseph L Glash Practical HPLC
method development Wiley India Pvt Ltd 2004 15-45
54 Center for Drug Evaluation and Research US Food and Drug
Administration Safety testing of drug metabolites Feb 2008
55 HPFBTPD [Canada guidelines] Metabolites in comparative
Bioavailability studies Draft May 2004
56 Center for Drug Evaluation and Research US Food and Drug
Administration Drug Metabolism Interactions Nov 1999
57 Center for Drug Evaluation and Research US Food and Drug
Administration Drug interaction studies-study design data analysis
and implications for dosing and labeling Draft Sep 2006
58 D M Brahankar sunil B Jaiswal Phase-I reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan New Delhi 2008 117-137
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
12 Chow SC Liu JP Design and Analysis of Bioavailability and
Bioequivalence Studies - Revised and Expanded 2nd Edition Marcel
Dekker Inc New York 1992
13 Chow SC and Liu JP Design and analysis of bioavailability and
bioequivalence studies 3rd Edition Chapman HallCRC Press Taylor
amp Francis [New York] 2008
14 Blume H and Midha KK Report of Consensus Meeting Bio-
international rsquo92 Conference on Bioavailability Bioequivalence and
Pharmacokinetic Studies Bad Homburg Germany 20-22 May 1992
Eur J Pharm Sci 1165-171
15 Boddy AW Snikeris FC Kringle RO Wei GCG Oppermann
JA and Midha KK An approach for widening the bioequivalence
acceptance limits in the case of highly variable drugs Pharm Res
1995121865-1868
16 Marzo A Clinical pharmacokinetic registrations file for NDA and
ANDA procedures Pharmacological research Chapter-36 1997 425-
450
17 Therapeutic Products Directorate Minister of Health Health Canada
Discussion paper on Bioequivalence requirements - highly variable
drugs and highly variable drug products issues and options Expert
Advisory Committee on Bioavailability and Bioequivalence [EAC-BB]
Meeting June 26-27 2003
18 Department of Health and Human Services US Food and Drug
Administration Bioavailability and bioequivalence requirements
Drugs for human use Code of federal regulations Title 21 Volume 5
Chapter I Part 32024 Apr 2011
19 Robert P Heaney Factors Influencing the Measurement of
Bioavailability Taking Calcium as a Model J Nutr 131 2001 1344-
1348
20 Westlake WJ Bioavailability and bioequivalence pharmaceutical
formulations In Peace KE [Ed] Biopharmaceu -tical statistics for
drug development Marcell Dekker New York 1988 329-352
21 Investigation of bioavailability and bioequivalence The rules
governing medicinal products in European Community Vol III
addendum-2 1991 149-169
22 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry-waiver of in vivo bioavailability
and bioequivalence studies for immediate-release solid oral dosage
forms based on a biopharmaceutics classification system August
2000 1-13
23 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry-Bioequivalence
recommendations for specific products Jun 2010 1-4
24 Center for Drug Evaluation and Research US Food and Drug
Administration Inspections of clinical facilities and analytical
laboratories conducting bioequivalence studies submitted in ANDAS
Dec 2000 1-5
25 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use General
considerations for clinical trials-E8 ICH triplicate efficacy guidelines
Version-4 Jul 1997 1-13
26 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Structure and
content of clinical study reports-E3 ICH triplicate efficacy guidelines
Version-4 Nov 1995
27 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Guideline for good
clinical practice-E6 [R1] ICH triplicate efficacy guidelines Version-4
June 1996
28 Michael J McGraw Adam N George Shawn P Shearn and Rigel L
Hall editors Principles of Good Clinical Practice Pharmaceutical
Press 1st edition 2010 245-256
29 Central Drugs Standard Control Organization Directorate General of
Health Services Government of India Guide lines on Good clinical
practice 2005
30 World Health Organization Guidelines for GCP for trials on
pharmaceutical products WHO technical report series Annex-3 850
1995 1-35
31 Department of Health and Human Services US Food and Drug
Administration Protection of human subjects Code of federal
regulations Title 21 Volume-1 Chapter- I part 50
32 Department of Health and Human Services US Food and Drug
Administration Institutional review boards Code of federal
regulations Title 21 volume-1 chapter- I part 56
33 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for institutional review boards clinical
investigators and sponsors Exception from Informed Consent
Requirements for Emergency Research July 2006
34 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Investigator responsibilities
protecting the rights safety and welfare of study subjects Oct 2009
35 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Development
safeties update report-E2F ICH Triplicate efficacy guidelines Version
4 Aug 2010
36 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Clinical safety data
management definitions and standards for expedited reporting-E2A
ICH Triplicate efficacy guidelines Version 4 Oct 1994
37 D M Brahankar sunil B Jaiswal Pharmacokinetics Basic
considerations Biopharmaceutics and Pharmacokinetics Vallabh
Prakashan 2008 212-229
38 Center for Drug Evaluation and Research US Food and Drug
Administration ERIn vitroIn vivo correlations Bioavailability and
Bioequivalence Sep 1997
39 D M Brahankar sunil B Jaiswal Invitro-invivo correlation
Bioavailability and Bioequivalence Biopharmaceutics and
Pharmacokinetics A Treatise Vallabh Prakashan 2008 282-305
40 WHO-Research and training in tropical diseases Handbook of good
laboratory practice Quality practices for regulated non-clinical
research and development 2nd edition 2008 9-40
41 Department of Health and Human Services US Food and Drug
Administration Good laboratory practices for nonclinical laboratory
studies Code of federal regulations Title 21 Volume 1 Chapter- I
Part 58
42 Organisation for Economic Co-operation and Development Good
laboratory practice OECD principles and guidance for compliance
monitoring OECD publishing 2005 13-26
43 Jurg PSeiler Good laboratory practice 2nd edition Springer-Verlag
Berlin Heidelberg European Union 2005 59-103
44 Sandy Weinberg Good laboratory practice regulations 3rd edition
revised and expanded Taylor amp Francis e-Library New York 2005
127-148
45 Willa Y Garner Maureen S Barge James P Ussary Good laboratory
practice standards Applications for field and laboratory studies
American Chemical Society 1992 124-132
46 Milton A Anderson GLP essentials a concise guide to good
laboratory practice 2nd edition Interpharm Press 2002 15-30
47 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Exposure-response
relationships-study design data analysis and regulatory applications
Apr 2003
48 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Statistical
principles for clinical trials-E9 ICH harmonised tripartite efficacy
guideline Feb 1998
49 Schuirmann DJ A comparison of the two one-sided test procedure
and the power approach for assessing the equivalence of average
bioavailability J Pharmacokinet Biopharm 15 1987 657-680
50 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Guidance for industry
Statistical approaches establishing bioequivalence Jan 2001 1-45
51 Murray R Spiegel Curve fitting Regression Planes and Correlation
Coefficients Probability and Statistics 2004 278-327
52 Steinijans VW and Hauschke D Update on the statistical analysis of
bioequivalence studies International journal of clinical pharmacology
therapy and toxicology 30[1] 1992 45-50
53 Lloyd R Snyder Joseph J Kirkland Joseph L Glash Practical HPLC
method development Wiley India Pvt Ltd 2004 15-45
54 Center for Drug Evaluation and Research US Food and Drug
Administration Safety testing of drug metabolites Feb 2008
55 HPFBTPD [Canada guidelines] Metabolites in comparative
Bioavailability studies Draft May 2004
56 Center for Drug Evaluation and Research US Food and Drug
Administration Drug Metabolism Interactions Nov 1999
57 Center for Drug Evaluation and Research US Food and Drug
Administration Drug interaction studies-study design data analysis
and implications for dosing and labeling Draft Sep 2006
58 D M Brahankar sunil B Jaiswal Phase-I reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan New Delhi 2008 117-137
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
forms based on a biopharmaceutics classification system August
2000 1-13
23 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry-Bioequivalence
recommendations for specific products Jun 2010 1-4
24 Center for Drug Evaluation and Research US Food and Drug
Administration Inspections of clinical facilities and analytical
laboratories conducting bioequivalence studies submitted in ANDAS
Dec 2000 1-5
25 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use General
considerations for clinical trials-E8 ICH triplicate efficacy guidelines
Version-4 Jul 1997 1-13
26 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Structure and
content of clinical study reports-E3 ICH triplicate efficacy guidelines
Version-4 Nov 1995
27 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Guideline for good
clinical practice-E6 [R1] ICH triplicate efficacy guidelines Version-4
June 1996
28 Michael J McGraw Adam N George Shawn P Shearn and Rigel L
Hall editors Principles of Good Clinical Practice Pharmaceutical
Press 1st edition 2010 245-256
29 Central Drugs Standard Control Organization Directorate General of
Health Services Government of India Guide lines on Good clinical
practice 2005
30 World Health Organization Guidelines for GCP for trials on
pharmaceutical products WHO technical report series Annex-3 850
1995 1-35
31 Department of Health and Human Services US Food and Drug
Administration Protection of human subjects Code of federal
regulations Title 21 Volume-1 Chapter- I part 50
32 Department of Health and Human Services US Food and Drug
Administration Institutional review boards Code of federal
regulations Title 21 volume-1 chapter- I part 56
33 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for institutional review boards clinical
investigators and sponsors Exception from Informed Consent
Requirements for Emergency Research July 2006
34 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Investigator responsibilities
protecting the rights safety and welfare of study subjects Oct 2009
35 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Development
safeties update report-E2F ICH Triplicate efficacy guidelines Version
4 Aug 2010
36 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Clinical safety data
management definitions and standards for expedited reporting-E2A
ICH Triplicate efficacy guidelines Version 4 Oct 1994
37 D M Brahankar sunil B Jaiswal Pharmacokinetics Basic
considerations Biopharmaceutics and Pharmacokinetics Vallabh
Prakashan 2008 212-229
38 Center for Drug Evaluation and Research US Food and Drug
Administration ERIn vitroIn vivo correlations Bioavailability and
Bioequivalence Sep 1997
39 D M Brahankar sunil B Jaiswal Invitro-invivo correlation
Bioavailability and Bioequivalence Biopharmaceutics and
Pharmacokinetics A Treatise Vallabh Prakashan 2008 282-305
40 WHO-Research and training in tropical diseases Handbook of good
laboratory practice Quality practices for regulated non-clinical
research and development 2nd edition 2008 9-40
41 Department of Health and Human Services US Food and Drug
Administration Good laboratory practices for nonclinical laboratory
studies Code of federal regulations Title 21 Volume 1 Chapter- I
Part 58
42 Organisation for Economic Co-operation and Development Good
laboratory practice OECD principles and guidance for compliance
monitoring OECD publishing 2005 13-26
43 Jurg PSeiler Good laboratory practice 2nd edition Springer-Verlag
Berlin Heidelberg European Union 2005 59-103
44 Sandy Weinberg Good laboratory practice regulations 3rd edition
revised and expanded Taylor amp Francis e-Library New York 2005
127-148
45 Willa Y Garner Maureen S Barge James P Ussary Good laboratory
practice standards Applications for field and laboratory studies
American Chemical Society 1992 124-132
46 Milton A Anderson GLP essentials a concise guide to good
laboratory practice 2nd edition Interpharm Press 2002 15-30
47 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Exposure-response
relationships-study design data analysis and regulatory applications
Apr 2003
48 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Statistical
principles for clinical trials-E9 ICH harmonised tripartite efficacy
guideline Feb 1998
49 Schuirmann DJ A comparison of the two one-sided test procedure
and the power approach for assessing the equivalence of average
bioavailability J Pharmacokinet Biopharm 15 1987 657-680
50 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Guidance for industry
Statistical approaches establishing bioequivalence Jan 2001 1-45
51 Murray R Spiegel Curve fitting Regression Planes and Correlation
Coefficients Probability and Statistics 2004 278-327
52 Steinijans VW and Hauschke D Update on the statistical analysis of
bioequivalence studies International journal of clinical pharmacology
therapy and toxicology 30[1] 1992 45-50
53 Lloyd R Snyder Joseph J Kirkland Joseph L Glash Practical HPLC
method development Wiley India Pvt Ltd 2004 15-45
54 Center for Drug Evaluation and Research US Food and Drug
Administration Safety testing of drug metabolites Feb 2008
55 HPFBTPD [Canada guidelines] Metabolites in comparative
Bioavailability studies Draft May 2004
56 Center for Drug Evaluation and Research US Food and Drug
Administration Drug Metabolism Interactions Nov 1999
57 Center for Drug Evaluation and Research US Food and Drug
Administration Drug interaction studies-study design data analysis
and implications for dosing and labeling Draft Sep 2006
58 D M Brahankar sunil B Jaiswal Phase-I reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan New Delhi 2008 117-137
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
investigators and sponsors Exception from Informed Consent
Requirements for Emergency Research July 2006
34 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Investigator responsibilities
protecting the rights safety and welfare of study subjects Oct 2009
35 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Development
safeties update report-E2F ICH Triplicate efficacy guidelines Version
4 Aug 2010
36 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Clinical safety data
management definitions and standards for expedited reporting-E2A
ICH Triplicate efficacy guidelines Version 4 Oct 1994
37 D M Brahankar sunil B Jaiswal Pharmacokinetics Basic
considerations Biopharmaceutics and Pharmacokinetics Vallabh
Prakashan 2008 212-229
38 Center for Drug Evaluation and Research US Food and Drug
Administration ERIn vitroIn vivo correlations Bioavailability and
Bioequivalence Sep 1997
39 D M Brahankar sunil B Jaiswal Invitro-invivo correlation
Bioavailability and Bioequivalence Biopharmaceutics and
Pharmacokinetics A Treatise Vallabh Prakashan 2008 282-305
40 WHO-Research and training in tropical diseases Handbook of good
laboratory practice Quality practices for regulated non-clinical
research and development 2nd edition 2008 9-40
41 Department of Health and Human Services US Food and Drug
Administration Good laboratory practices for nonclinical laboratory
studies Code of federal regulations Title 21 Volume 1 Chapter- I
Part 58
42 Organisation for Economic Co-operation and Development Good
laboratory practice OECD principles and guidance for compliance
monitoring OECD publishing 2005 13-26
43 Jurg PSeiler Good laboratory practice 2nd edition Springer-Verlag
Berlin Heidelberg European Union 2005 59-103
44 Sandy Weinberg Good laboratory practice regulations 3rd edition
revised and expanded Taylor amp Francis e-Library New York 2005
127-148
45 Willa Y Garner Maureen S Barge James P Ussary Good laboratory
practice standards Applications for field and laboratory studies
American Chemical Society 1992 124-132
46 Milton A Anderson GLP essentials a concise guide to good
laboratory practice 2nd edition Interpharm Press 2002 15-30
47 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Exposure-response
relationships-study design data analysis and regulatory applications
Apr 2003
48 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Statistical
principles for clinical trials-E9 ICH harmonised tripartite efficacy
guideline Feb 1998
49 Schuirmann DJ A comparison of the two one-sided test procedure
and the power approach for assessing the equivalence of average
bioavailability J Pharmacokinet Biopharm 15 1987 657-680
50 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Guidance for industry
Statistical approaches establishing bioequivalence Jan 2001 1-45
51 Murray R Spiegel Curve fitting Regression Planes and Correlation
Coefficients Probability and Statistics 2004 278-327
52 Steinijans VW and Hauschke D Update on the statistical analysis of
bioequivalence studies International journal of clinical pharmacology
therapy and toxicology 30[1] 1992 45-50
53 Lloyd R Snyder Joseph J Kirkland Joseph L Glash Practical HPLC
method development Wiley India Pvt Ltd 2004 15-45
54 Center for Drug Evaluation and Research US Food and Drug
Administration Safety testing of drug metabolites Feb 2008
55 HPFBTPD [Canada guidelines] Metabolites in comparative
Bioavailability studies Draft May 2004
56 Center for Drug Evaluation and Research US Food and Drug
Administration Drug Metabolism Interactions Nov 1999
57 Center for Drug Evaluation and Research US Food and Drug
Administration Drug interaction studies-study design data analysis
and implications for dosing and labeling Draft Sep 2006
58 D M Brahankar sunil B Jaiswal Phase-I reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan New Delhi 2008 117-137
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
45 Willa Y Garner Maureen S Barge James P Ussary Good laboratory
practice standards Applications for field and laboratory studies
American Chemical Society 1992 124-132
46 Milton A Anderson GLP essentials a concise guide to good
laboratory practice 2nd edition Interpharm Press 2002 15-30
47 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Exposure-response
relationships-study design data analysis and regulatory applications
Apr 2003
48 International conference on harmonisation of technical requirements
for registration of pharmaceuticals for human use Statistical
principles for clinical trials-E9 ICH harmonised tripartite efficacy
guideline Feb 1998
49 Schuirmann DJ A comparison of the two one-sided test procedure
and the power approach for assessing the equivalence of average
bioavailability J Pharmacokinet Biopharm 15 1987 657-680
50 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for Industry Guidance for industry
Statistical approaches establishing bioequivalence Jan 2001 1-45
51 Murray R Spiegel Curve fitting Regression Planes and Correlation
Coefficients Probability and Statistics 2004 278-327
52 Steinijans VW and Hauschke D Update on the statistical analysis of
bioequivalence studies International journal of clinical pharmacology
therapy and toxicology 30[1] 1992 45-50
53 Lloyd R Snyder Joseph J Kirkland Joseph L Glash Practical HPLC
method development Wiley India Pvt Ltd 2004 15-45
54 Center for Drug Evaluation and Research US Food and Drug
Administration Safety testing of drug metabolites Feb 2008
55 HPFBTPD [Canada guidelines] Metabolites in comparative
Bioavailability studies Draft May 2004
56 Center for Drug Evaluation and Research US Food and Drug
Administration Drug Metabolism Interactions Nov 1999
57 Center for Drug Evaluation and Research US Food and Drug
Administration Drug interaction studies-study design data analysis
and implications for dosing and labeling Draft Sep 2006
58 D M Brahankar sunil B Jaiswal Phase-I reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan New Delhi 2008 117-137
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
59 D M Brahankar sunil B Jaiswal Phase-II reactions
Biotransformation of drugs Biopharmaceutics and Pharmacokinetics
A Treatise Vallabh Prakashan 2008 138-146
60 Gurdeep R Chatwal Sham K Anand Introduction to Instrumental
Chemical Analysis Instrumental methods of chemical analysis
Himalaya Publishing House 2009 11-124
61 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch Sampling Standardization and Calibration Tools of
Analytical Chemistry Fundamentals of Analytical Chemistry 8th
edition Thomson BrooksCole Thomson Asia Pvt Ltd Singapore
2004 175-227
62 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 1- Sample preparation and chromatography
Process development Biopharm November 2001 28-38
63 D M Brahankar sunil B Jaiswal Excreation of drugs
Biopharmaceutics and Pharmacokinetics A Treatise Vallabh
Prakashan New Delhi 2008 178-201
64 N Weng Novel liquid chromatographic-tandem mass spectrometric
methods using silica columns and aqueous-organic mobile phases for
quantitative analysis of polar ionic analytes in biological fluids j
Chromatogr B 754 2001 387-399
65 Richard FVenn Phsico-Chemical properties of drugs and metabolities
and their extraction from biological material Principles and Practice
of bioanalysis 2007 110-140
66 N Weng Development and validation of a sensitive method for the
hydromorphone in human plasma by normal phase liquid
chromatography-tandem mass spectrometry j Pharm Biomed Anal
23 2000 697-704
67 P Lu Process purification of polypeptides and proteins by reversed-
phase column chromatography Misconceptions and Reality
biopharm 14[9] 2001 28-35
68 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Bioanalytical Method
Validation May 2001
69 Brazilian Sanitary Surveillance Agency Bioanalytical method
validation ANVISA guidelines May 2003
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
70 Brazilian Sanitary Surveillance Agency Explanation of the
implementation of re no 8992003 - validation of bioanalytical
methods ANVISA guidelines Jun 2008
71 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices volume-1 [clinics
analytics and statistics ANVISA guidelines 2002
72 European Directorate for the Quality of Medicines and Health Care
Guideline on validation of analytical procedures PAPHOMCL [05]
47 De OMCL network of the council of Europe quality assurance
document Jun 2005
73 International conference on harmonization of technical requirements
for registration of pharmaceuticals for human use Validation of
analytical procedures Text and Methodology-Q2 [R1] ICH
harmonised tripartite quality guidelines Version-4 Nov 2005
74 Center for Drug Evaluation and Research US Food and Drug
Administration Reviewer guidance- Validation of chromatogram -phic
methods Nov 1994
75 Brazilian Sanitary Surveillance Agency Manual for good
bioavailability and bioequivalence practices Volume-2 [Micropipette
Water for Analysis Instrumentation] ANVISA guidelines 2002
76 Center for Drug Evaluation and Research US Food and Drug
Administration Guidance for industry Analytical procedures and
methods validation- chemistry manufacturing and controls
documentation Draft guidance Aug 2000
77 Frank Chow Arlene Ocampo Paul Vogel Steven Lum and Nhan Tran
Current challenges for FDA-regulated bioanalytical laboratories
performing human BABE studies Part III Selected discussion topics
in bioanalytical LCMSMS method validation Journal of Quality
Assurance 12 2009 22-30
78 C T Viswanathan Surendra Bansal Brian Booth Anthony J
Destefano Mark J Rose Jeffrey Sailstad Vinod P Shah Jerome P
Skelly Patrick G Swann and Russell Weiner Quantitative
bioanalytical methods validation and implementation Best practices
for chromatographic and ligand binding assays The AAPS journal 9
[1] Article-4 2007
79 Bansal S and Destefano A Key elements of bioanalytical method
validation for small molecules American association of
pharmaceutical sciences journal 9[1] 2007 109-114
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
80 Roger Causon Validation of chromatographic methods in biomedical
analysis viewpoint and discussion Journal of Chromatography B
Biomedical Sciences and Applications 689[1] 7 Feb 1997 175-180
81 King R Bonfiglio R Fernandez-Metzler C Miller-Stein C Olah T
Mechanistic investigation of ionization suppression in electrospray
ionization J Am Soc Mass spectrom 11 2000 942-950
82 DL Buhrman PI Price and PJ Rudewicz Quantitation of sr27417
in human plasma using electrospray liquid chromatography-tandem
mass spectrometry a study of ion suppression J Am Soc Mass
spectrom 7 1996 1099-1105
83 J R Lang S Bolton A comprehensive method validation strategy for
bioanalytical applications in the pharmaceutical industry-2
Statistical analyses Journal of Pharmaceutical and Biomedical
Analysis 9[6] 1991 435-442
84 Dadgar D Burnett PE Issues in evaluation of bioanalytical method
selectivity and drug stability JPharmBiomedAnal 14 1995 23-31
85 Gurdeep R Chatwal Sham K Anand Errors Accuracy and Precision
Instrumental Methods of Chemical Analysis Himalaya Publishing
House New Delhi 2009 21-26
86 Swartz ME and Krull IS Validation of chromatographic methods
Pharmaceutical Technology 22[33] 1998 104-119
87 Gary DChristian High performance liquid chromatography
Analytical Chemistry Wiley India Pvt Ltd 2007 537-548
88 Gurdeep R Chatwal Sham K Anand High performance liquid
chromatography Instrumental Methods of Chemical Analysis
Himalaya Publishing House New Delhi 2009 2624-2639
89 Douglas A Skoog Donald M West F James Holler Stanley R
Crouch High performance liquid chromatography Fundamentals of
Analytical Chemistry 8th edition Thomson BrooksCole Thomson
Asia Pte Ltd Singapore 2004 973-995
90 Ghulam A Shabir HPLC method development and validation for
pharmaceutical analysis Pharmaceutical Technology Mar 2004
91 MS Lee and ED Kerns LCMS applications in drug development
Mass spectrom Rev 18 1999 187-279
92 Gurdeep R Chatwal Sham K Anand Mass Spectrometry
Instrumental Methods of Chemical Analysis Himalaya Publishing
House 2009 2272-2302
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
93 YRSharma Mass spectroscopy Principles and chemical
applications Elementary Organic Spectroscopy SChand amp Company
Ltd New Delhi 2005 234-281
94 N Weng Simultaneous development of six LC-MS-MS methods for
the determination of multiple analytes in human plasma J Pharm
Biomed Anal 2001
95 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Part 2-Large-scale LCMSMS and automation Process
Development Biopharm Jan 2002 22-27
96 Naidong Wong and Timothy DJHalls Systematic troubleshooting for
LCMSMS Process Development Biopharm Mar 2002 102-120
97 Garg Deependra Singh Swarnlata Saraf and S Saraf Aceclofenac a
potent non-steroidal anti-inflammatory pharmainfonet 2005-2006
98 Gureje O Von Korff M Simon Ge Gater R Persistent pain and well-
being a World Health Organization study in primary care journal of
American medical association 280[2] Jul 1998 147-51
99 Dooley M Spencer CM Dunn CJ Aceclofenac a reappraisal of its use
in the management of pain and rheumatic disease drugs 61[9]
2001 1351-78
100 DAhartman SJOchalski and RPCarlson The effects of anti-
inflammatory and antiallergic drugs on cytokine release after
stimulation of human whole blood by lipopolysaccharide and
zymosana Inflammation research 44 [7] 269-274
101 Lemmel EM Leeb B DE Bast J Aslanidis S Patient and physician
satisfaction with aceclofenac results of the European observational
cohort study [experience with aceclofenac for inflammatory pain in
daily practice] Aceclofenac is the treatment of choice for patients and
physicians in the management of inflammatory pain 18[3] 2002
146-53
102 Yamazaki R Kawai S Matsuzaki T Kaneda N Hashimoto S
Yokokura T et al Aceclofenac blocks prostaglandin E2 production
following its intracellular conversion into cyclo-oxygenase
inhibitors European journal of pharmacology 329 1997 181-7
103 Blot L Marcelis A Devogelaer JP Manicourt DH Effects of diclofenac
aceclofenac and meloxicam on the metabolism of proteoglycans and
hyaluronan in osteoarthritic human cartilage British journal of
pharmacology 131[7] Dec 2000 1413-21
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
104 Santanu Ghosh and BB Barik Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product International journal of medicine
and medical sciences 1 [9] Sept 2009 375-382
105 Pawar VT Pishawika SA More HN Spectrophotometric estimation
of aceclofenac and paracetamol from tablet dosage form Current
Pharma Research 1[1] Oct-Dec 2010
106 Jyotesh Jain Riddhish Patadia Divyesh Vanparia Renu Chauhan
Shailesh Shah Dual wavelength spectrophotometric method for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in their combined tablet dosage form International journal of
pharmacy and pharmaceutical sciences 2[4] 2010
107 Santosh Gandhi Padmanabh Deshpande Vivek Rajmane Tanmay
Dodal Jitesh Parab Method development and validation for
simultaneous estimation of drotaverine hydrochloride and aceclofenac
in tablet dosage form by RP-HPLC International journal of
pharmaceutical sciences review and research 4[3] Sep-Oct 2010
108 Gopinath R Rajan S Meyyanathan SN Krishnaveni N and Suresh A
RP-HPLC method for simultaneous estimation of paracetamol and
aceclofenac in tablets Indian journal of pharmaceutical sciences
69[1] 2007 137-140
109 Prashant musmade G Subramanian and KK Srinivasan High-
performance liquid chromatography and pharmacokinetics of
aceclofenac in rats Anal Chim Acta 585 [1] 28 Feb 2007 103-109
110 N H Zawilla M Abdul Azim Mohammad NMEL Kousya S M EL-
moghazy aly Determination of aceclofenac in bulk and
pharmaceutical formulations Journal of pharmaceutical and
biomedical analysis 27 [1-2] 1 Jan 2002 243-251
111 Santosh Bhalerao Santosh Tambe Vikas Pareek Rupali Shinde Lalit
Kumar Gupta A solid-liquid extraction and high performance thin
layer chromatographic determination of diacerein and aceclofenac in
pharmaceutical tablet dosage form Asian journal of pharmaceutical
and clinical research 3[1] Jan-Mar 2010
112 JBagyalakshmi Sajna John and TKRavi Development and
validation of simultaneous estimation of paracetamol aceclofenac and
rabeprazole in combined tablet dosage formulation by HPTLC method
Pelagia research library Der Pharmacia Sinica 2 [2] 2011 43-50
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
113 Hye Suk Lee Chang Kyun Jeonga Sung Jin Choia Sang Beom
Kima Mi Hyun Leea Geon Koa and Dong Hwan Sohna
Simultaneous determination of aceclofenac and diclofenac in human
plasma by narrow bore HPLC using column-switching Journal of
pharmaceutical and biomedical analysis 23[5] Oct 2000 775-781
114 Godse VP Deodhar MN Bhosale AV Sonawane RA Sakpal PS
Borkar DD and Bafana YS Reverse phase HPLC method for
determination of aceclofenac and paracetamol in tablet dosage form
Asian j Research Chem 2[1] Jan-Mar 2009
115 Vishnu Choudhari Kunal Ingale Madhusmita Sahoo Pratima Syal
Snehal Ingale Santosh Shinde Abhijit Sutar Bhanudas Kuchekar
Development and validation of a RP-HPLC-PDA method for
simultaneous estimation of drotaverine and aceclofenac in a
combined dosage form int J Res Pharm Sci 1[3] 2010 253-258
116 Laxminarayan R Parry IWH Smith DL Klein E should new
antimalarial drugs be subsidized J health econ 29 2010 445-456
117 World Health Organisation [2006] WHO guidelines for the treatment
of malaria 2nd edition 1 may 2010
118 World health Organisation [2009] World Malaria Report 1 may 2010
119 Jared N Cumming Poonsakdi Ploypraditha and Gary H Posnera
Antimalarial activity of artemisinin [qinghaosu] and related trioxanes
mechanism[s] of action Advances in pharmacology 37 1996 253-
297
120 Washington DC Institute of medicine of the national
academies saving lives buying time Economics of malaria drugs in
an age of resistance National Academies Press 2004
121 Mccombie SC Treatment seeking for malaria a review of recent
research Soc Sci Med 43 1996 933-945
122 Williams HA Jones CO A critical review of behavioral issues related
to malaria control in sub-Saharan Africa Soc Sci Med 59 2004 501-
523
123 Roll back malaria-2007[RBM] Affordable medicines facility-malaria
[AMFm] 5 may 2010
124 Talisuna A Grewal P Rwakimari JB Mukasa S Jagoe G et al Cost
is killing patients Subsidising effective antimalarials Lancet 374
2009 1224-1226
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
125 Goodman C Brieger W Unwin A Mills A Meek S et al Medicine
sellers and treatment in sub-Saharan Africa Am J Trop Med Hyg
77[6] 2007 203-218
126 Smith LA Jones C Meek S Webster J Provider practice and user
behavior interventions to improve prompt and effective treatment of
malaria do we know what works Am j Trop Med Hyg 80[3] 2009
326-335
127 Oxfam Challenging the myths about private healthcare in poor
countries Blind optimism Oxfam briefing paper 3 may 2010
128 Noor AM Gething PM Alegana VM Patil A Hay SI et al The risks of
malaria infection in Kenya BMC Infectious Diseases 9 2009 180
129 Kangwana BB Njogu J Wasunna B Kedenge SV Memusi DN et al
Malaria drug shortages in Kenya a major failure to provide access to
effective treatment Am J Trop Med Hyg 80 2009 737-738
130 Van Vugt M Looareesuwan S Wilairatana P MC Gready R Villegas
L Gathmann I Mull R Brockman A White Nj Nosten F Artemether-
lumefantrine for the treatment of multidrug-resistant falciparum
malaria Transactions of the Royal Society of Tropical Medicine and
Hygeine 94[5] Sep-Oct 2000 545-8
131 Sabot OJ Mwita A Cohen JM Ipuge Y Gordon M et al Piloting the
global subsidy the impact of subsidized artemisinin-based
combination therapies distributed through private drug shops in rural
Tanzania Plos one 4[9] 2009 6857
132 Sabot O Yeung S Pagnoni F Gordon M Petty Net al Distribution of
artemisinin-based combination therapies through private-sector
channels RFF Discussion Paper 2009 08-43
133 Dalessandro U Talisuna M Boelaert M Should artemisinin-based
combination treatment be used in the home-based manaalaria Trop
Med Int Health 10 2005 1-2
134 Richard K Haynes Simone C Vonwiller Extraction of artemisinin
and artemisinic acid preparation of artemether and new analogues
Transactions of the Royal Society of Tropical Medicine and Hygiene
88[1] June 1994 23-26
135 Dharmarajan Sriram Vajja Sambasiva Rao Kondapalli Venkata
Gowri Chandrasekhar Perumal Yogeeswari Progress in the research
of artemisinin and its analogues as antimalarials Natural Product
Research formerly natural product letters 18[6] 2004 503-527
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
136 N Sandrenan A Sioufi J Godbillon C Netter M Donker C Van
Valkenburg Determination of artemether and its metabolite
dihydroartemisinin in plasma by high-performance liquid
chromatography and electrochemical detection in the reductive mode
Journal of chromatography-B 691[1] mar1997 145-153
137 D K Muhia E K Mberu and W M Watkins Differential extraction
of artemether and its metabolite dihydroartemisinin from plasma and
determination by high-performance liquid chromatography Journal of
Chromatography B Biomedical Sciences and Applications 660[1] 3
Oct 1994 196-199
138 Toufigh Gordi Elisabet Nielsena Zuoxiang Yub Douglas Wester
Lund and Michael Ashton Direct analysis of artemisinin in plasma
and saliva using coupled-column high-performance liquid
chromatography with a restricted-access material pre-column
Journal of Chromatography B Biomedical Sciences and Applications
742[1] 26 may 2000 155-162
139 Bonnie A Avery Krishna K Venkatesha and Mitchell a Avery Rapid
determination of artemisinin and related analogues using high-
performance liquid chromatography and an evaporative light
scattering detector Journal of chromatography B Biomedical
Sciences and Applications 730[1] 25 June 1999 71-80
140 Paktiya Teja-Isavadharm James O Peggins Thomas G Brewer
Nicholas J Whit H Kyle Webster and Dennis E Kyle Plasmodium
falciparum-based bioassay for measurement of artemisinin derivatives
in plasma or serum Antimicrobial agents and chemotherapy 48[3]
Mar 2004 954-960
141 Dwight L Mounta G Daniel Todda and V Navaratnamb Packed-
column supercritical fluid chromatography of artemisinin [qinghaosu]
with electron-capture detection Journal of Chromatography B
Biomedical Sciences and Applications 666[1] 7 April 1995 183-187
142 SS Mohamed SA Khalid SA Ward TSM Wan HPO Tang M
Zheng Simultaneous determination of artemether and its major
metabolite dihydroartemisinin in plasma by gas chromatography-
mass spectrometry-selected ion monitoring Journal of
Chromatography B 731 1999 251-260
143 PSahai RAVishwakarma SBharel AGulati MZAbdin PS
Srivastava and SKJain HPLC-Electrospray ionization mass
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
spectrometric analysis of antimalarial drug artemisinin Anal Chem
70[14] 1998 3084-3087
144 RK Haynes G Edwards C Souppart N Gauducheau N Sandrenan
and F Richard Development and validation of a high-performance
liquid chromatography-mass spectrometry assay for the
determination of artemether and its metabolite dihydro-artemisinin in
human plasma Journal of chromatography B 774 2002 195-203
145 Magalhaes IR Jabor VA Faria AM Collins CH Jardim IC Bonato PS
Determination of beta-artemether and its main metabolite
dihydroartemisinin in plasma employing liquid-phase micro extraction
prior to liquid chromatographic-tandem mass spectrometric analysis
Talanta 81[3] 15 may 2010 941-7
146 MRajanikanth KPMadhusudanan and RCGupta Liquid
chromatographic-mass spectrometric method for the determination of
α- β-arteether in rat serum Journal of chromatography B 783[2]
15 Jan 2003 391-399
147 The Merck Index 9th edition Rahway New Jersey Merck amp co inc
1976 50
148 Osol A and JE Hoover et al Remingtonrsquos pharmaceutical sciences
15th edition Easton Pennsylvania Mack publishing co 1975 850
149 Wittmann T Paradowski L Ducrotte P Bueno L Andro Aelestrain
MC Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome-a randomized double-blind placebo-controlled study
Alimentary Pharmacology amp Therapeutics 31[6] 2010 615-24
150 T Wittmann L Paradowski P Ducrott L Bueno MC Andro
delestrain Clinical trial the efficacy of alverine citratesimeticone
combination on abdominal paindiscomfort in irritable bowel
syndrome - a randomized double-blind placebo-controlled study
Alimentary pharmacology amp therapeutics 31[6] 2010 615-624
151 Coelho AM Jacob L Fioramonti J and Bueno L Rectal
antinociceptive properties of alverine citrate are linked to antagonism
at the 5-HT1A receptor subtype J Pharm Pharmacology 53 2001
1419-1426
152 Hayase M Hashitani H Suzuki H Kohri K and Brading A Evolving
mechanisms of action of alverine citrate on phasic smooth muscles
Br j pharmacol 152[8] Dec 2007 1228-1238
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
153 Bouvier M Grimaud JC Abysique A and Chiarelli P Effects of
alverine on the spontaneous electrical activity and nervous control of
the proximal colon of the rabbit Gastroenterol clin Biol 16 1992
334-338
154 Abysique A Lucchini S Orsoni P Mei N and Bouvier M Effects of
alverine citrate on cat intestinal mechanoreceptor responses to
chemical and mechanical stimuli Aliment Pharmacol Ther 13
1999 561-566
155 Arhan M Koklu S Koksal AS Yolcu OF Koruk S Koruk I and
Kayacetin E Alverine citrate induced acute hepatitis World j
gastroenterol 10[15] 2004 2303-2304
156 Noel A Gomesa Avdhoot Lauda Ashutosh Pudage Santosh S Joshi
Vikas V Vaidyaa and Jayram A Tandel Validated LC-MSMS method
for determination of alverine and one of its hydroxy metabolites in
human plasma along with its application to a bioequivalence study
Journal of Chromatography B 877 2009 197-206
157 Rahul C Gavhane Ketan K Nerurkar Ashok M Kalamkar Mitesh
R Patil Satish G Pingale and Prafullakumar Kulkarni Liquid
chromatographytandem mass spectrometry for the simultaneous
determination of alverine and its metabolite monohydroxy alverine in
human plasma application to a pharmacokinetic study E-journal of
chemistry 8[1] 2011 201-211
158 Ghosh C Jha V Ahir R Shah S Shinde CP Chakraborty BS A rapid
and most sensitive liquid chromatographytandem mass spectrometry
method for simultaneous determination of alverine and its major
metabolite para hydroxy alverine in human plasma application to a
pharmacokinetic and bioequivalence study Drug Testing Analysis
2[6] Jun 2010 284-91
159 Herbert JM Frehel D Bernat A Badorc A Savi P Delebassee D
Kieffer G Defreyn G Maffrand JP Clopidogrel hydrogenosulfate Drug
Future 18 1993 107-112
160 Karsten Schror Clinical pharmacology of the adenosine diphosphate
[ADP] receptor antagonist clopidogrel Vascular Medicine 3 1998
247ndash251
161 Sugidachi A Asai F Ogawa T Inoue T and Koike H The in vivo
pharmacological profile of CS-747 a novel antiplatelet agent with
platelet ADP receptor antagonist properties B J Pharmacol 129
2000 1439-1446
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
162 Savi P Labouret C Delesque N Guette F Lupker J and Herbert JM
P2Y12- a new platelet ADP receptor target of Clopidogrel Biophys
Biochem Res Commun 283 2001 379-383
163 Savi P Combalbert J Gaich C Rouchon MC Maffrand JP Berger Y
and Herbert JM The anti aggregating activity of Clopidogrel is due to
a metabolic activation by hepatic cytochrome P450-1A Thromb
Haemostasis 72 1994 313-317
164 Savi P Pereillo JM Uzabiaga F Combalbert J Picard C Maffrand JP
Pascal M and Herbert JM Identification and biological activity of the
metabolite of Clopidogrel Thromb Haemostasis 84 2000 891-896
165 Herbert JM Savi P and Maffrand JP Biochemical and
pharmacological properties of Clopidogrel a new ADP receptor
antagonist Eur Heart J 1 [Suppl A] 1999 31-40
166 Robinson A Hillis J Neal C Leary AC The validation of a
bioanalytical method for the determination of clopidogrel in human
plasma Journal of Chromatography B Analyt Technol Biomed Life
Sci [2] 848 2007 344-54
167 Shin BS Yoo SD Determination of clopidogrel in human plasma by
liquid chromatographytandem mass spectrometry application to a
clinical pharmacokinetic study Biomed Chromatogr 21[9] 2007
883-9
168 Ramakrishna V S Nirogi Vishwottam N Kandikere Manoj Shukla
Koteshwara Mudigonda Santosh Maurya and Ravikumar Boosi
Quantification of clopidogrel in human plasma by sensitive liquid
chromatographytandem mass spectrometry Rapid Communications
in Mass Spectrometry 20[11] 1695-1700
169 Effat Souri Hassan Jalalizadeh Abbas Kebriaee-Zadeh Maral
Shekarchi Afshin Dalvandi Validated HPLC method for
determination of carboxylic acid metabolite of clopidogrel in human
plasma and its application to a pharmacokinetic study Biomedical
Chromatography 20[12] 1309-1314
170 Singh Sonu S Sharma Kuldeep Barot Deepak Ram Mohan P and
Lohray vidya B Estimation of carboxylic acid metabolite of clopidogrel
in wistar rat plasma by HPLC and its application to a
pharmacokinetic study Journal of chromatography-B 821[2] 2005
173-180
171 Gholamreza Bahrami High-performance liquid chromatographic
determination of inactive carboxylic acid metabolite of clopidogrel in
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
human serum Application to a bioequivalence study J Chrom 864
[1-2] 15 Mar 2008 168-172
172 Hanna Ksycinska Piotr Rudzk and Mirosława Bukowska-Kiliszek
Determination of clopidogrel metabolite [sr26334] in human plasma
by LC-MS journal of pharmaceutical and biomedical analysis 41[2]
3 may 2006 533-539
173 Takahashi M Pang H Kawabata K Farid NA and Kurihara A
Quantitative determination of clopidogrel metabolite in human plasma
by LC-MSMS J Pharm Biomed Anal 48[4] 2008 1219-24
174 Xavier Delavenne Thierry Basset Paul Zufferey Nora Malouk Silvy
Laporte Patrick Mismetti Ultra-performance LC MSMS method for
quantification of clopidogrel active metabolite Journal of Separation
Science33[13] July 2010 1968ndash1972
175 JL Herman Generic method for on-line extraction of drug
substances in the presence of biological matrices using turbulent flow
chromatography Rapid communications in mass spectrometry 16[5]
March 2002 421-426
176 UAbshagen A New Molecule with vasodilating and [beta]-
adrenoceptor blocking properties Journal of Cardiovascular
Pharmacology 10 1987 S23
177 KStrein GSponer BMuller-Beckmann W Bartsch Pharmacological
Profile of Carvedilol a Compound with [beta]-Blocking and
Vasodilating Properties Journal of Cardiovascular Pharmacology 10
1987 S33
178 W Bartsch G Sponer K Strein B Muller-Beckmann L Kling E
Bohm U Martin HO Borbe Pharmacological characteristics of the
stereoisomers of carvedilol Eur J Clin Pharmacol 38 1990 S104
179 G Sponer K Strein B Muller-Beckmann W Bartsch Studies on
the Mode of Vasodilating Action of Carvedilol Journal of
Cardiovascular Pharmacology 10 1987 S42
180 RR Ruffolo jr M Gellai JP Hieble RN Willette AJ Nichols The
pharmacology of carvedilol Eur J Clin Pharmacol 38 1990 S82
181 MA Pfeffer LW Stevenson Beta-adrenergic blockers and survival in
heart failure The New Engalnd Journal of Medicine 334 1996 1396
182 M Packer MR Bristow JN Cohn WS Colucci MB Fowler EM
Gilbert NH Shusterman The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure The New England
Journal of Medicine 334 1996 1349
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
183 SA Fahlbusch D Tsikas C Mehls FM Gutzki RH Boger JC
Frolich DO Stichtenoth Effects of carvedilol on oxidative stress in
human endothelial cells and healthy volunteers Eur J Clin
Pharmacol 60 2004 83
184 C De Mey K Breithaupt J Schloos G Neugebauer D Palm GG
Belz Dose-effect and pharmacokinetic-pharmacodynamic
relationships of the beta 1-adrenergic receptor blocking properties of
various doses of carvedilol in healthy humans Clin Pharmacol Ther
55 1994 329
185 F Varin LX Cubeddu JR Powell Liquid chromatographic assay
and disposition of carvedilol in healthy volunteers J Pharm Sci 75
1986 1195
186 P Ptacek J Macek J Klima Liquid chromatographic determination
of carvedilol in human plasma Journal of Chromatography B 789[2]
15 Jun 2003 405-410
187 Eric Yang Sherry Wang John Kratz and Matthew J Cyronak
Stereoselective analysis of carvedilol in human plasma using
HPLCMSMS after chiral derivatization Journal of Pharmaceutical
and Biomedical Analysis 36[3] 15 Nov 2004 609-615
188 N Hokama N Hobara H Kameya S Ohshiro M Sakanashi Rapid
and simple micro-determination of carvedilol in rat plasma by high-
performance liquid chromatography Journal of Chromatography B
Biomedical Sciences and Applications 732 [1] 10 Sep 1999 233-238
189 EJ Eisenberg WR Patterson GC Kahn High-performance liquid
chromatographic method for the simultaneous determination of the
enantiomers of carvedilol and its O-desmethyl metabolite in human
plasma after chiral derivatization Journal of Chromatography B
Biomedical Sciences and Applications 493 1989 105-115
190 LClohs KMMcErlane Comparison between capillary electrophoresis
and high-performance liquid chromatography for the stereoselective
analysis of carvedilol in serum Journal of Pharmaceutical and
Biomedical Analysis 31[3] 10 Mar 2003 407-412
191 JOravcova DSojkova WLindner Comparison of the Hummel-
Dreyer method in high-performance liquid chromatography and
capillary electrophoresis conditions for study of the interaction of
[RS]- [R]- and [S]-carvedilol with isolated plasma proteins
Applications 12 Jul 1996 349-357
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
192 H Spahn W Henke P Langguth J Schloos E Mutschler
Measurement of carvedilol enantiomers in human plasma and urine
using S-naproxen chloride for chiral derivatization Archiv der
Pharmazie 323[8] 1990 465-469
193 G Neugebauer W Akpan B Kaufmann K Reiff Stereoselective
disposition of carvedilol in man after intravenous and oral
administration of the racemic compound Eur J Clin Pharmacol 38
1990 108-111
194 D Tenero S Boike D Boyle B Ilson HF Fesniak S Brozena D
Jorkasky Steady-state pharmacokinetics of carvedilol and its
enantiomers in patients with congestive heart failure Clin Pharmacol
40[8] 1 Aug 2000 844-853
195 Ney Carter do Carmo Borgesa et al Quantification of carvedilol in
human plasma by high-performance liquid chromatography coupled
to electrospray tandem mass spectrometry Application to
bioequivalence study Journal of Chromatography B 822[1-2] 5 Aug
2005 253-262
196 M Gergov JN Robson E Duchoslav I Ojanpera Automated liquid
chromatographictandem mass spectrometric method for screening β-
blocking drugs in urine Journal of Mass Spectrometry 35[7] Jul
2000 912-918
197 K Reiff Quantification of carvedilol in human plasma by high-
performance liquid chromatography coupled to electrospray tandem
mass spectrometry application to bioequivalence study J
Chromatogr 413 2005 355
198 SN Anavekar et al Pharmacokinetics and antihypertensive effects of
low dose clonidine during chronic therapy J Clin Pharmacol 29[4] 1
Apr 1989 321-326
199 Jorg Huwyler Gert Fricker Michael Torok Markus Schneider and
Jurgen Drewe Transport of Clonidine across Cultured Brain
Microvessel Endothelial Cells Pharmacology 282[1] 1997 81-85
200 Methylphenidate and Clonidine Help Children with ADHD and Tics
National Institute of Neurological Disorders and Stroke 2002
201 Schapiro NA Dude you dont have Tourettersquos Tourettersquos syndrome
beyond the tics Pediatr Nurs 28[3] May-Jun 2002 243-6 249-53
202 Guang-Ming KE Li Wang Hui-Yong Xue Wan-Liang LU Xuan
Zhang Qiang Zhang and Hong-You Guo In Vitro and in Vivo
Characterization of a Newly Developed Clonidine Transdermal Patch
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
for Treatment of Attention Deficit Hyperactivity Disorder in Children
Biol Pharm Bull 28[2] 2005 305-310
203 Determination of chlorthalidone and clonidine hydrochloride in
tablets by HPLC J Chromatogr Sci 21[1] Jan 1983 43-5
204 CChu WFBayne FTTao LGSchmitt JEShaw Determina -tion
of submicrogram quantities of Clonidine in biological fluids Journal
of Pharmaceutical Sciences 68[1] 72-74
205 Edlumd PO Paalzow LK Quantitative gas-liquid chromatogram -phic
determination of clonidine in plasma Acta Pharmacol Toxicol
[Copenh] 40[1] Jan 1977 145-52
206 C Muller M Ramic S Harlfinger C Huumlnseler M Theisohn and B
Roth Sensitive and convenient method for the quantification of
Clonidine in serum of pediatric patients using liquid
chromatographytandem mass spectrometry Journal of
Chromatography A 1139[2] 19 Jan 2007 221-227
207 Mary Pelzer Thomas Addison Wenbao Li Xiangyu Jiang Naidong
Weng Development and validation of a liquid chromatography-
tandem mass spectrometry method using silica column and aqueous-
organic mobile phase for the analysis of clonidine as low as 10 pgml
in human serum Journal of Liquid Chromatography amp Related
Technologies 25[7] May 2002 1019 -1032
208 Janssen Pharmaceutica Products Sporanox [Lumefantrine] injection
US Food and Drug Administration 2002
209 MVan Vugt ABrockman BGemperli CLuxemburger IGathmann
CRoyce TSlight SLooareesuwan NJWhite FNosten Randomized
Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in
Treatment of Multidrug Resistant Falciparum Malaria Antimicrobial
Agents and Chemotherapy 42[1] Jan 1998 135-139
210 Price RN Uhlemann AC van Vugt M Brockman A Hutagalung R
Nair S Nash D Singhasivanon P Anderson TJ Krishna S White NJ
Nosten F Molecular and pharmacological determinants of the
therapeutic response to artemether-lumefantrine in multidrug-
resistant Plasmodium falciparum malaria Clin Infect Dis 42[11] 1
Jun 2006 1570-7
211 Zurovac D Ndhlovu AKRowe DH Hamer DMThea and
RWSnow Treatment of paediatric malaria during a period of drug
transition to artemether-lumefantrine in Zambia Cross sectional
study BMJ 2005 331-734
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
212 De Beule K and Van Gestel J Pharmacology of Lumefantrine Drugs
61[S1] 2001 27-37
213 Conway SP Etherington C Peckham DG Brownlee KG Whitehead A
and Cunliffe H Pharmacokinetics and safety of Lumefantrine in
patients with cystic fibrosis Journal of Antimicrobial Chemotherapy
53 2004 841-847
214 Lefevre G Carpenter P Souppart C Schimidli H McClean M
Stypinski D Pharmacokinetics and electrocardiographic
pharmacodynamics of artemether-lumefantrine [Riamet] with
concomitant administration of ketoconazole in healthy subjects Br J
Clin Pharmacol 54[5] Nov 2002 485-92
215 Ter KF NJ White PHolloway GPasvol and SKrishna Plasmodim
falciparum in vitro studies of the pharmocodynamic properties of
drugs used for the treatment of severe malaria Exp Parasitol 76
1993 85-95
216 CHatz SAbdulla RMull DSchellenberg IGathmann Pkibatala
HPBeck MTanner CRoyce Efficacy and safety of CGP 56697
[artemether and benflumetol] compared with chlroquine to treat acute
falciparum malaria in Tanzanian children aged 1-5 years Tropical
Medicine and Interantional Health 3 1998 498
217 MV Vugt P Wilairatana B Gemperli I Gathmann L Phaipun A
Brockman C Luxemburger NJ White F Nosten and S
Looareesuwan Efficacy of six doses of artemether-lumefantrine
[benflumetol] in multidrug-resistant Plasmodium falciparum malaria
Am J Trop Med Hyg 60[6] 1999 936-942
218 Danielle Colussi Carole Parisot Francois Legay and Gilbert Lefegravevre
Binding of artemether and lumefantrine to plasma proteins and
erythrocytes European Journal of Pharmaceutical Sciences 9[1] Oct
1999 9-16
219 Annerberg A Singtoroj T Tipmanee P White NJ Day NP Lindegardh
N High throughput assay for the determination of lumefantrine in
plasma J Chromatogr B Analyt Technol Biomed Life Sci 822[1-2] 5
Aug 2005 330-3
220 N Lindegardh A Annerberga D Blessborn Y Bergqvist N Day
and NJ Development and validation of a bioanalytical method using
automated solid-phase extraction and LC-UV for the simultaneous
determination of lumefantrine and its desbutyl metabolite in plasma
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
White Journal of Pharmaceutical and Biomedical Analysis 37[5] 29
Apr 2005 1081-1088
221 CAHovinga Levetiracetam a novel antiepileptic drug
Pharmacotherapy 21[11] 2001 1375-88
222 EA Wilson MJ Brodie New antiepileptic drugs Baillieres Clin
Neurol 5[4] 1996 723-47
223 William E Rosenfelda Selim Benbadisb Pascal Edrichc Carlo
Alberto Tassinarid Edouard Hirsche Levetiracetam as add-on
therapy for idiopathic generalized epilepsy syndromes with onset
during adolescence Analysis of two randomized double-blind
placebo-controlled studies 85[1] Jul 2009 72-80
224 E Perucca M Bialer The clinical pharmacokinetics of the newer
antiepileptic drugs Focus on topiramate zonisamide and tiagabine
Clin Pharmacokinet 31[1] 1996 29-46
225 Eric Snoecka Philippe Jacqmina Maria Laura Sargentini-Maierb
Modeling and simulation of intravenous levetiracetam
pharmacokinetic profiles in children to evaluate dose adaptation
rules 76[2] Sept 2007 140-147
226 Nathan B Fountaina Joan A Conryb Ildefonso Rodriguez-Leyvac
Juvenal Gutierrez-Moctezumad Edubijes Salase Rene Coupezf
Armel Stockisf Zhihong [Sarah] Lue Prospective assessment of
levetiracetam pharmacokinetics during dose escalation in 4- to 12-
year-old children with partial-onset seizures on concomitant
carbamazepine or valproate 74[1] Apr 2007 60-69
227 N Isoherranen B Yagen S Soback M Roeder V Schurig and
MBialer Pharmacokinetic analysis of levetiracetam and its
enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs
Epilepsia 42 2001 825-830
228 R Coupez R Straetemans G Sehgal A Stockis ZS Lu J
Levetiracetam relative bioavailability and bioequivalence of a 10
oral solution [750 mg] and 750-mg tablets ClinPharmacol 43[12]
2003 1370-6
229 Ganesan M Rauthan SK Yadav SS Pandey Y tripathi P
Validated liquid chromatographic ultra violet method for the
quantization of levetiracetam in human plasma using liquid-liquid
extraction International journal of pharmaceutical sciences and
research [IJPSR] 1[1] 2010 1-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
230 TA Vermeij PM Edelbroek High-performance liquid
chromatographic and megabore gas-liquid chromatographic
determination of levetiracetam [ucb L059] in human serum after
solid-phase extraction J Chromatogr B Biomed Appl 662[1] 2 Dec
1994 134-9
231 Jens Martens-Lobenhoffer Stefanie M Bode-Boger Determination of
levetiracetam in human plasma with minimal sample pretreatment
Journal of Chromatography B 819 2005 197-200
232 N Isoherranen M Roeder S Soback B Yagen V Schurig MBialer
Enantioselective analysis of levetiracetam and its enantiomer R-alpha-
ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion
trap mass spectrometric detection J Chromatogr B Biomed Sci Appl
745[2] 18 Aug 2000 325-32
233 Pitt B Konstam MA Overview of angiotensin II Am J Cardiol 82
1998 47-49
234 Unger T Significance of angiotensin type 1 receptor blockade why
are angiotensin II receptor blockers different Am J Cardiol 84 1999
9-15
235 Willenheimer R Dahl B Rydberg E Erhardt L Angiotensin II receptor
antagonists Eur Heart J 20 1999 997-1008
236 Zhang P Zhang Y Chen X Li R Yin J Zhong D Pharmacokinetics of
telmisartan in healthy Chinese subjects after oral administration of
two dosage levels Arzneimittelforschung 56 2006 569-73
237 Ebner T Heinzel G Prox A Beschke K Wachsmuth H Disposition
and Chemical Stability of Telmisartan 1-O-Acylglucuronide Drug
Metab Dispos 27 1999 1143-1149
238 Chen B Liang Y Wang Y Deng FL Zhou P Guo F and Huang L
Determination of telmisartan in human blood plasma Part I
Immunoassay development Anal Chim Acta 540 2005 367-373
239 Torrealday N Gonzalez L Alonso RM Jimenez RM Lastra EO
Determination of telmisartan in human blood plasma J Pharm
Biomed Anal 32 2003 847-857
240 Maotian TX Song JF Li N Determination of telmisartan in human
blood plasma Anal Bioanal Chem 377 2003 1184-1189
241 Maotian TX Song J Liang Y Determination of telmisartan in human
blood plasma J Pharm Biomed Anal 34 2004 681-687
242 Kondo T Yoshida K Yoshimura Y Motohashi M Tanayama S
Characterization of Conjugated Metabolites of a New Angiotensin II
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
Receptor Antagonist Candesartan Cilexetil in Rats by Liquid
ChromatographyElectrospray Tandem Mass Spectrometry Following
Chemical Derivatization J Mass Spec 31 1996 873-878
243 Gonzalez L Akesolo U Jimenez RM Alonso RM Determination of
telmisartan in human blood plasma Part II Liquid chromatography-
tandem mass spectrometry method development Comparison to
immunoassay and pharmaco kine -tic study Analytica Chimica Acta
560 2006 41-49
244 Yan T Li H Deng L Guo Y Yu W Fawcett JP Zhang D Cui Y Gu J
Liquid chromatographic-tandem mass spectrometric method for the
simultaneous quantitation of telmisartan and hydrochlorothiazide in
human plasma J Pharm Biomed Anal 48 2008 1225-9
245 Ferreiros N Dresen S Alonso RM Weinmann W Validated
quantitation of angiotensin II receptor antagonists [ARA-II] in human
plasma by liquid-chromatography-tandem mass spectrometry using
minimum sample clean-up and investigation of ion suppression Ther
Drug Monit 29 2007 824-34
246 Li P Wang Y Wang Y Tang Y Fawcett JP Cui Y Gu J
Determination of telmisartan in human plasma by liquid
chromatography-tandem mass spectrometry J Chromatogr B Analyt
Technol Biomed Life Sci 828 2005 126-9
247 ACrosignani KDSetchell PInvernizzi ALarghi CMRodrigues
MPodda Clinical pharmacokinetics of therapeutic bile acids Clin
Pharmacokinet 30[5] 1996 333-58
248 SScalia RScagliarini PPazzi Evaluation of ursodeoxycholic acid
bioavailability from immediate- and sustained-release preparations
using gas chromatography-mass spectrometry and high-performance
liquid chromatography Arzneimittelforschung 50[2] Feb 2000 129-
34
249 SScalia PGiunchedi PPazzi UConte Enhancement of
ursodeoxycholic acid bioavailability by cross-linked sodium
carboxymethyl cellulose J Pharmacy and Pharmacology 52[4] Apr
2000 383-388
250 AKBatta SShefer MBatta GSalen Effect of chenodeoxycholic acid
on biliary and urinary bile acids and bile alcohols in cerebrotendinous
xanthomatosis monitoring by high performance liquid
chromatography Journal of Lipid Research 26[6] 1985 690-698
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
251 MNobilis MPour JKunes JKopecky JKvetina ZSvoboda
KSladkova JVortel High-performance liquid chromatographic
determination of ursodeoxycholic acid after solid phase extraction of
blood serum and detection-oriented derivatization JPharm Biomed
Anal 24[5-6] 2001 937-47
252 FNakayama MNakagaki Quantitative determination of bile acids in
bile with reversed-phase high-performance liquid chromatography
JChromatogr 183 [3] 1980 287-93
253 WSwobodnik UKluppelberg JGWechsler MVolz GNormandin
HDitschuneit Rapid and accurate reversed-phase high-performance
liquid chromatographic determination of conjugated bile acids in
human bile for routine clinical applications Therapeutic control
during gallstone dissolution therapy JChromatogr 339[2] 1985
263-71
254 RGatti ARoda CCerre DBonazzi VCavrini HPLC-Fluorescence
determination of individual free and conjugated bile acids in human
serum Biomedical Chromatography 11[1] 1997 11-15
255 VCavrini RGatti ARoda CCerre PRoveri HPLC-fluorescence
determination of bile acids in pharmaceuticals and bile after
derivatization with 2-bromoacetyl-6-methoxynaphthalene J Pharm
Biomed Anal 11[8] 1993 761-70
256 ESLianidou DSPapastathopoulos PASiskos Determination of
ursodeoxycholic acid in serum by a new fluorometric enzymatic
method using 7β-hydroxysteroid dehydrogenase from Clostridium
absonum Analytical Biochemistry 179[2] 1989 341-346
257 JGoto KWatanabe HMiura TNambara TLida Studies on
steroids CCXXVIII Trace analysis of bile acids by gas
chromatography-mass spectrometry with negative ion chemical
ionization detection J Chromatogr 388[2] 1987 379-87
258 AKBatta RArora GSalen GSTint DEskreis SKatz
Characterization of serum and urinary bile acids in patients with
primary biliary cirrhosis by gas-liquid chromatography-mass
spectrometry effect of ursodeoxycholic acid treatment Journal of
Lipid Research 30[12] 1989 1953-1962
259 KKuriyama YBan TNakashima TMurata Simultaneous
determination of biliary bile acids in rat Electron impact and
ammonia chemical ionization mass spectrometric analyzes of bile
acids Steroids 34[6] 1979 717-728
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9
260 ARoda CCerre PSimoni CVaccari APistillo Determination of free
and amidated bile acids by high-performance liquid chromatography
with evaporative light-scattering mass detection Journal of Lipid
Research 33[9] 1992 1393-402
261 SPerwaiz BTuchweber DMignault TGilat IMYousef
Determination of bile acids in biological fluids by liquid
chromatography-electrospray tandem mass spectrometry Journal of
Lipid Research 42[1] 2001 114-9